Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir HIV-1 viral decay and pharmacokinetics in semen in antiretroviral-naive patients
2013-003243-36Phase 3Completed
- Sponsor
- Bellvitge University Hospital
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dolutegravir in Human immunodeficiency virus infection type 1, sponsored by Bellvitge University Hospital. Primary endpoint: HIV-1 viral load in semen over 24 weeks. Started Nov 2013; status: completed.
02
Drugs
dolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2013-003243-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003243-36.